![Samuel Backenroth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Samuel Backenroth
Keine laufenden Positionen mehr
Profil
Samuel I.
Backenroth is the founder of Orphion Therapeutics, Inc., Eyexora Global, Inc., DepYmed, Inc., ImmuneWalk Therapeutics, Inc. Former jobs include Chief Financial Officer at Vascular Biogenics Ltd. and Notable Labs Ltd., CFO, Secretary & Principal Accounting Officer at Ohr Pharmaceutical, Inc. from 2012 to 2019, and Chief Financial Officer, Secretary & Treasurer at Neubase Therapeutics, Inc. and NeuBase Therapeutics, Inc. from 2019 to 2021.
Education includes undergraduate studies at Touro College.
Aktive Positionen von Samuel Backenroth
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von Samuel Backenroth
| Unternehmen | Position | Ende |
|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Finanzdirektor/CFO | 30.09.2021 |
Neubase Therapeutics, Inc. /Old/
 Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops peptide-nucleic acid antisense oligonucleotide platform | Finanzdirektor/CFO | 01.01.2021 |
Ohr Pharmaceutical, Inc.
 Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pharmaceuticals for the treatment of serious and unmet medical needs | Finanzdirektor/CFO | 01.01.2019 |
Ausbildung von Samuel Backenroth
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
10
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Touro College
 Touro College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Develops novel treatments for atherosclerosis and cancer | Health Technology |
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pharmaceuticals for the treatment of serious and unmet medical needs | Health Technology |
DepYmed, Inc.
 DepYmed, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of breast cancer | Health Technology |
Neubase Therapeutics, Inc. /Old/
Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops peptide-nucleic acid antisense oligonucleotide platform | Health Technology |
NeuBase Therapeutics, Inc.
 NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders | Health Technology |
Orphion Therapeutics, Inc.
 Orphion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel gene therapies for the treatment of genetic disorders | Health Technology |
Wählen Sie MarketScreener 
